Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
about
Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomasDose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline.Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamideGuidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdomCost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.Pharmacological therapies for Liposarcoma.Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.Multivariate Markov models for the conditional probability of toxicity in phase II trials.Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma.Managing sarcoma: where have we come from and where are we going?Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue.Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy.Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma G
P2860
Q24234049-2AF92DD9-95F2-4CC9-8C37-C76E2AC428D8Q33379481-39A40229-562A-4F61-8C97-D6571D6056CFQ33406493-ECFC3EF4-156E-4D25-9571-45FA65B6D6D5Q35214578-21B20647-EED5-4B05-A06C-F653F65BD8B7Q35220462-E856D34D-2C85-496C-821A-0A7E172CDF40Q36191321-B3F0D74C-EC05-49DC-ABDA-C1A20AB57CA0Q36611978-C8B1FAF8-256A-4D6F-9A33-764D4569A1EAQ36731032-90246D53-5B83-4BBA-9110-BAD8A20D85C3Q37330372-E912AADB-37CD-451D-B557-250A249C2635Q37886394-0BD5D6E2-116D-4036-A74B-D29464FBDB41Q38797843-B4DF00B0-C510-47A0-8671-5957A9F96F83Q38991731-2B6384A0-8035-4BB2-A710-11D9A3420805Q39743562-65FDE496-FB00-42A2-A2DA-BB2574C3CEEAQ40650639-3AD8B0F7-66B5-413F-8739-A7437C727F2EQ41963479-B7FBB3FC-E8E4-4F23-9767-FEFCD47EECC2Q41988197-E9FA9E16-F97A-4FF9-B9C5-2E8725168720Q49627984-B7AA764D-A7AC-472B-8B7C-04D4B96347DCQ55350018-80CD493A-702F-4D1E-9B53-5964F4A1CFDBQ57570892-406DE874-EF5C-4BB7-A3A5-A1DBBB5427E9
P2860
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Randomized phase II evaluation ...... prognosis soft tissue sarcoma.
@ast
Randomized phase II evaluation ...... prognosis soft tissue sarcoma.
@en
type
label
Randomized phase II evaluation ...... prognosis soft tissue sarcoma.
@ast
Randomized phase II evaluation ...... prognosis soft tissue sarcoma.
@en
prefLabel
Randomized phase II evaluation ...... prognosis soft tissue sarcoma.
@ast
Randomized phase II evaluation ...... prognosis soft tissue sarcoma.
@en
P2093
P356
P1476
Randomized phase II evaluation ...... prognosis soft tissue sarcoma.
@en
P2093
Cornelius J McGinn
Francis P Worden
Janet S Biermann
Jeremy M G Taylor
Kirstin M Leu
Laurence H Baker
Mark M Zalupski
Rashmi Chugh
Vernon K Sondak
P304
P356
10.1200/JCO.2005.05.108
P407
P577
2005-01-01T00:00:00Z